Cell therapy for Parkinson's disease with induced pluripotent stem cells.
Cell therapy
Central nervous system
Parkinson’s disease
Pluripotent stem cells
Transplantation
Journal
Inflammation and regeneration
ISSN: 1880-9693
Titre abrégé: Inflamm Regen
Pays: England
ID NLM: 101479577
Informations de publication
Date de publication:
27 Feb 2023
27 Feb 2023
Historique:
received:
16
11
2022
accepted:
20
02
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
28
2
2023
Statut:
epublish
Résumé
Parkinson's disease (PD) is the second most common neurodegenerative disease and a prime target of cell therapies. In fact, aborted fetal tissue has been used as donor material for such therapies since the 1980s. These cell therapies, however, suffer from several problems, such as a short supply of donor materials, quality instability of the tissues, and ethical restrictions. The advancement of stem cell technologies has enabled the production of donor cells from pluripotent stem cells with unlimited scale, stable quality, and less ethical problems. Several research groups have established protocols to induce dopamine neural progenitors from pluripotent stem cells in a clinically compatible manner and confirmed efficacy and safety in non-clinical studies. Based on the results from these non-clinical studies, several clinical trials of pluripotent stem cell-based therapies for PD have begun. In the context of immune rejection, there are several modes of stem cell-based therapies: autologous transplantation, allogeneic transplantation without human leukocyte antigen-matching, and allogeneic transplantation with matching. In this mini-review, several practical points of stem cell-based therapies for PD are discussed.
Identifiants
pubmed: 36843101
doi: 10.1186/s41232-023-00269-3
pii: 10.1186/s41232-023-00269-3
pmc: PMC9969678
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
16Subventions
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20bm0704054
Informations de copyright
© 2023. The Author(s).
Références
Trends Immunol. 2015 Oct;36(10):569-577
pubmed: 26431936
Brain. 2005 Jul;128(Pt 7):1498-510
pubmed: 15872020
Stem Cell Reports. 2013 Sep 26;1(4):283-92
pubmed: 24319664
Nat Commun. 2020 Jul 6;11(1):3369
pubmed: 32632153
Nature. 2017 Aug 30;548(7669):592-596
pubmed: 28858313
N Engl J Med. 2020 May 14;382(20):1926-1932
pubmed: 32402162
Sci Transl Med. 2010 Jun 30;2(38):38ra46
pubmed: 20592420
Ann Neurol. 2003 Sep;54(3):403-14
pubmed: 12953276
Cell Rep. 2019 Sep 24;28(13):3462-3473.e5
pubmed: 31553914
Blood. 2013 Aug 22;122(8):1341-9
pubmed: 23741009
Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7
pubmed: 30853558
Nat Biotechnol. 2017 Aug;35(8):765-772
pubmed: 28504668
Cell Stem Cell. 2014 Jan 2;14(1):121-30
pubmed: 24388175
Nat Biotechnol. 2009 Mar;27(3):275-80
pubmed: 19252484
Cell Stem Cell. 2021 Feb 4;28(2):343-355.e5
pubmed: 33545081
N Engl J Med. 2001 Mar 8;344(10):710-9
pubmed: 11236774
Nat Commun. 2016 Oct 14;7:13097
pubmed: 27739432
Cell Stem Cell. 2021 Feb 4;28(2):217-229.e7
pubmed: 33545080
Prog Brain Res. 2010;184:265-94
pubmed: 20887880
Stem Cell Reports. 2014 Mar 06;2(3):337-50
pubmed: 24672756
Regen Ther. 2020 Sep 15;13:18-22
pubmed: 33490319
Nat Commun. 2017 Aug 30;8(1):385
pubmed: 28855509
JAMA Neurol. 2014 Jan;71(1):83-7
pubmed: 24217017